Resveratrol is active against Leishmania amazonensis: In vitro effect of its association with amphotericin B

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 10, 2014, Pages 6197-6208

  Ferreira, Christian ^a   Soares, Deivid Costa ^a   Cunha Do Nascimento, Michelle Tanny ^a   Pinto da Silva, Lucia Helena ^b   Sarzedas, Carolina Galväo ^a   Tinoco, Luzineide Wanderley ^a   Saraiva, Elvira Maria ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL RURAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ARGINASE; INTERLEUKIN 4; NITRIC OXIDE; RESVERATROL; ANTIPROTOZOAL AGENT; RISTOCETIN; STILBENE DERIVATIVE;

AMASTIGOTE; ANIMAL CELL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CELL ADHESION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME INHIBITION; IC50; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA; MACROPHAGE; MOUSE; NONHUMAN; PARASITE SURVIVAL; PERITONEUM MACROPHAGE; PHAGOCYTOSIS; PROMASTIGOTE; PROTON NUCLEAR MAGNETIC RESONANCE; XTT ASSAY; BIOLOGY; DRUG EFFECTS; DRUG POTENTIATION; GENETICS; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

AMPHOTERICIN B; ANTIPROTOZOAL AGENTS; COMPUTATIONAL BIOLOGY; DRUG SYNERGISM; LEISHMANIA; MAGNETIC RESONANCE SPECTROSCOPY; RISTOCETIN; STILBENES;

EID: 84907279955     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00093-14     Document Type: Article

References (62)

1. Alvar J, Vêlez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M, the WHO Leishmaniasis Control Team. 2012. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 7:e35671. http://dx.doi.org/10.1371/journal.pone.0035671.
2. Barrett MP, Croft SL. 2012. Management of trypanosomiasis and leishmaniasis. Br. Med. Bull. 104:175-196. http://dx.doi.org/10.1093/bmb/lds031.
3. Ouellette M, Drummelsmith J, Papadopoulou B. 2004. Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resist. Updat. 7:257-266. http://dx.doi.org/10.1016/j.drup.2004.07.002.
4. Berman J. 2003. Current treatment approaches to leishmaniasis. Curr. Opin. Infect. Dis. 16:397-401. http://dx.doi.org/10.1097/00001432-200310000-00005.
5. Santos DO, Coutinho CE, Madeira MF, Bottino CG, Vieira RT, Nascimento SB, Bernardino A, Bourguignon SC, Corte-Real S, Pinho RT, Rodrigues CR, Castro HC. 2008. Leishmaniasis treatment-a challenge that remains: a review. Parasitol. Res. 103:1-10. http://dx.doi.org/10.1007,/s00436-008-0943-2.
6. Soto J, Arana BA, Toledo J, Rizzo N, Vega JC, Díaz A, Luz M, Gutiérrez P, Arboleda M, Berman JD, Junge K, Engel J, Sindermann H. 2004. Miltefosine for New World cutaneous leishmaniasis. Clin. Infect. Dis. 38:1266-1272. http://dx.doi.org/10.1080/38332I.
7. Sindermann H, Engel J. 2006. Development of miltefosine as an oral treatment for leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 100(Suppl 1):S17-S20. http://dx.doi.org/10.1016/j.trstmh.2006.02.010.
8. Kubo M, Kimura Y, Shin H, Haneda T, Tani T, Namba K. 1981. Studies on the antifungal substance of crude drug: 2. On the roots of Polygonum cuspidatum (Poligonaceae). Shoyakugaku Zasshe. 35:58-61.
9. Kimura Y, Ohminam H, Okuda H, Baba K, Kozawa M, Archi S. 1983. Effects of stilbene components of roots of Polygonum ssp. on liver injury in peroxidised oil-fed rats. Planta Med. 49:51-54. http://dx.doi.org/10.1055/s-2007-969810.
10. Hillis WE, Hart JH, Yazaki Y. 1974. Polyphenols of Eucalyptus sideroxylon wood. Phytochemistry 13:1591-1595. http://dx.doi.org/10.1016/0031-9422(74)80334-1.
11. Langcake P, Cornford CA, Pryce RJ. 1979. Identification of pterostilbene as a phytoalexin of Vitis vinifera leaves. Phytochemistry 18:1025-1028. http://dx.doi.org/10.1016/S0031-9422(00)91470-5.
12. Pirola L, Fröjdö S. 2008. Resveratrol: one molecule, many targets. IUBMB Life 60:323-332. http://dx.doi.org/10.1002/iub.47.
13. Baur JA, Sinclair DA. 2006. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 5:493-506. http://dx.doi.org/10.1038/nrd2060.
14. Pervaiz S. 2003. Resveratrol: from grapevines to mammalian biology. FASEB J. 17:1975-1985. http://dx.doi.org/10.1096/ij.03-0168rev.
15. Jang DS, Kang BS, Ryu SY, Chang IM, Min KR, Kim Y. 1999. Inhibitory effects of resveratrol analogs on unopsonized zymosan-induced oxygen radical production. Biochem. Pharmacol. 57:705-712. http://dx.doi.org/10.1016/S0006-2952(98)00350-5.
16. Chan MM. 2002. Antimicrobial effect of resveratrol on dermatophytes and bacterial pathogens of the skin. Biochem. Pharmacol. 63:99-104. http://dx.doi.org/10.1016/S0006-2952(01)00886-3.
17. Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G, Goldberg DM. 1995. The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin. Chim. Acta 235:207-219. http://dx.doi.org/10.1016/0009-8981(95)06045-1.
18. Docherty JJ, Fu MM, Stiffler BS, Limperos RJ, Pokabla CM, DeLucia AL. 1999. Resveratrol inhibition of herpes simplex virus replication. Antiviral Res. 43:145-155. http://dx.doi.org/10.3016/S0166-3542(99)00042-X.
19. Kedzierski L, Curtis JM, Kaminska M, Jodynis-Liebert J, Murias M. 2007. In vitro antileishmanial activity of resveratrol and its hydroxylated analogues against Leishmania major promastigotes and amastigotes. Parasitol. Res. 102:91-97. http://dx.doi.org/10.1007/s00436-007-0729-y.
20. Lucas IK, Kolodziej H. 2013. In vitro antileishmanial activity of resveratrol originates from its cytotoxic potential against host cells. Planta Med. 79:20-26. http://dx.doi.org/10.1055/s-0032-1328020.
21. Juan ME, Vinardell MP, Planas JM. 2002. The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J. Nutr. 132:257-260.
22. Lin CJ, Lee CC, Shih YL, Lin TY, Wang SH, Lin YE, Shih CM. 2012. Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. Free Radic. Biol. Med. 52:377-391. http://dx.doi.org/10.1016/j.freeradbiomed.2011.10.487.
23. George J, Singh M, Srivastava AK, Bhui K, Roy P, Chaturvedi PK, Shukla Y. 2011. Resveratrol and black tea polyphenol combination synergistically suppress mouse skin tumors growth by inhibition of activated MAPKs and p53. PLoS One 6:e23395. http://dx.doi.org/10.1371/journal.pone.0023395.
24. Vang O. 2013. What is new for resveratrol? Is a new set of recommendations necessary? Ann. N. Y. Acad. Sci. 1290:1-11. http://dx.doi.org/10.1111/nyas.12173.
25. Soares DC, Andrade AL, Delorenzi JC, Silva JR, Freire-de-Lima L, Falcäo CA, Pinto AC, Rossi-Bergmann B, Saraiva EM. 2010. Leishmanicidal activity of Himatanthus sucuuba latex against Leishmania amazonensis. Parasitol. Int. 59:173-177. http://dx.doi.org/10.1016/j.parint.2010.01.002.
26. Ferreira C, Soares DC, Barreto-Junior CB, Nascimento MT, Freire-de-Lima L, Delorenzi JC, Lima ME, Atella GC, Folly E, Carvalho TM, Saraiva EM, Pinto-da-Silva LH. 2011. Leishmanicidal effects of piperine, its derivatives, and analogues on Leishmania amazonensis. Phytochemistry 72:2155-2164. http://dx.doi.org/10.1016/j.phytochem.2011.08.006.
27. Roehm NW, Rodgers GH, Hatfield SM, Glasebrook AL. 1991. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J. Immunol. Methods 142:257-265. http://dx.doi.org/10.1016/00221759(91)90114-U.
28. Jain SK, Sahu R, Walker LA, Tekwani BL. 2012. A parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell line. J. Vis. Exp. 70:e4054. http://dx.doi.org/10.3791/4054.
29. Delorenzi JC, Freire-de-Lima L, Gattass CR, de Andrade Costa D, He L, Kuehne ME, Saraiva EM. 2002. In vitro activities of iboga alkaloid congeners coronaridine and 18-methoxycoronaridine against Leishmania amazonensis. Antimicrob. Agents Chemother. 46:2111-2115. http://dx.doi.org/10.1128/AAC.46.7.2111-2115.2002.
30. Soares DC, Calegari-Silva TC, Lopes UG, Teixeira VL, de Palmer Paixäo ICN, Cirne-Santos C, Bou-Habib DC, Saraiva EM. 2012. Dolabelladienetriol, a compound from Dictyota pfaffii algae, inhibits the infection by Leishmania amazonensis. PLoS Negl. Trop. Dis. 6:e1787. http://dx.doi.org/10.1371/journal.pntd.0001787.
31. Seifert K, Croft SL. 2006. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob. Agents Chemother. 50:73-79. http://dx.doi.org/10.1128/AAC.50.1.73-79.2006.
32. Tallarida RJ. 2000. Drug synergism and dose-effect data analysis. Chapman & Hall/CRC, New York, NY.
33. Ambit A, Fasel N, Coombs GH, Mottram JC. 2008. An essential role for the Leishmania major metacaspase in cell cycle progression. Cell Death Differ. 15:113-122. http://dx.doi.org/10.1038/sj.cdd.4402232.
34. Benitez D, Pezaroglo H, Martínez V, Casanova G, Cabrera G, Galanti N, González M, Cerecetto H. 2012. Study of Trypanosoma cruzi epimastigote cell death by NMR-visible mobile lipid analysis. Parasitology 139: 506-515. http://dx.doi.org/10.1017/S0031182011002150.
35. Poulsen MM, Jorgensen JO, Jessen N, Richelsen B, Pedersen SB. 2013. Resveratrol in metabolic health: an overview of the current evidence and perspectives. Ann. N. Y. Acad. Sci. 1290:74-82. http://dx.doi.org/10.1111/nyas.12141.
36. Dinesh N, Pallerla DS, Kaur PK, Kishore Babu N, Singh S. 2014. Exploring Leishmania donovani 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) as a potential drug target by biochemical, biophysical and inhibition studies. Microb. Pathog. 6:14-23. http://dx.doi.org/10.1016/j.micpath.2013.11.001.
37. Barrai A, Badaró R, Barral-Netto M, Grimaldi G, Jr, Momem H, Carvalho EM. 1986. Isolation of Leishmania mexicana amazonensis from the bone marrow in a case of American visceral leishmaniasis. Am. J. Trop. Med. Hyg. 35:732-734.
38. Barrai A, Pedral-Sampaio D, Grimaldi Júnior G, Momen H, McMahonPratt D, Ribeiro de Jesus A, Almeida R, Badaro R, Barral-Netto M, Carvalho EM. 1991. Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease. Am. J. Trop. Med. Hyg. 44:536-546.
39. Tolezano JE, Uliana SR, Taniguchi HH, Araújo MF, Barbosa JA, Barbosa JE, Floeter-Winter LM, Shaw JJ. 2007. The first records of Leishmania (Leishmania) amazonensis in dogs (Canis familiaris) diagnosed clinically as having canine visceral leishmaniasis from Araçatuba County, Sao Paulo State, Brazil. Vet. Parasitol. 149:280-284. http://dx.doi.org/10.1016/j.vetpar.2007.07.008.
40. Aleixo JA, Nascimento ET, Monteiro GR, Fernandes MZ, Ramos AM, Wilson ME, Pearson RD, Jeronimo SM. 2006. Atypical American visceral leishmaniasis caused by disseminated Leishmania amazonensis infection presenting with hepatitis and adenopathy. Trans. R. Soc. Trop. Med. Hyg. 100:79-82. http://dx.doi.org/10.1016/j.trstmh.2005.06.025.
41. Goldberg DE, Siliciano RF, Jacobs WR, Jr. 2012. Outwitting evolution: fighting drug-resistant TB, malaria, and HIV. Cell 148:1271-1283. http://dx.doi.org/10.1016/j.cell.2012.02.021.
42. Monzote L, Montalvo AM, Scull R, Miranda M, Abreu J. 2007. Combined effect of the essential oil from Chenopodium ambrosioides and antileishmanial drugs on promastigotes of Leishmania amazonensis. Rev. Inst. Med. Trop. Sao Paulo 49:257-260. http://dx.doi.org/10.1590/S0036-46652007000400012.
43. Corral MJ, González-Sánchez E, Cuquerella M, Alunda JM. 2014. In vitro synergistic effect of amphotericin B and allicin on Leishmania donovani and L. infantum. Antimicrob. Agents Chemother. 58:1596-1602. http://dx.doi.org/10.1128/AAC.00710-13.
44. de Morais-Teixeira E, Gallupo MK, Rodrigues LF, Romanha AJ, Rabello A. 2013. In vitro interaction between paromomycin sulphate and four drugs with leishmanicidal activity against three New World Leishmania species. J. Antimicrob. Chemother. 69:150-154. http://dx.doi.org/101093/jac/dkt318.
45. Wheeler RJ, Gluenz E, Gull K. 2011. The cell cycle of Leishmania: morphogenetic events and their implications for parasite biology. Mol. Microbiol. 79:647-662. http://dx.doi.org/10.1111/j.1365-2958.2010.07479.x.
46. Havens CG, Bryant N, Asher L, Lamoreaux L, Perfetto S, Brendie JJ, Werbovetz KA. 2000. Cellular effects of leishmanial tubulin inhibitors on L. donovani. Mol. Biochem. Parasitol. 110:223-236. http://dx.doi.org/10.1016/S0166-6853(00)00272-3.
47. Sarkar A, Sen R, Saha P, Ganguly S, Mandal G, Chatterjee M. 2008. An ethanolic extract of leaves of Piper betle (Paan) Linn mediates its antileishmanial activity via apoptosis. Parasitol. Res. 102:1249-1255. http://dx.doi,org/10.1007/s00436-008-0902-y.
48. Proto WR, Coombs GH, Mottram JC. 2013. Cell death in parasitic protozoa: regulated or incidental? Nat. Rev. Microbiol. 11:58-66. http://dx.doi.org/10.1038/nrmicro2929.
49. Benitez DA, Pozo-Guisado E, Alvarez-Barrientos A, FernandezSalguero PM, Castellón EA. 2007. Mechanisms involved in resveratrolinduced apoptosis and cell cycle arrest in prostate cancer-derived cell lines.J. Androl. 28:282-293. http://dx,doi.org/10.2164/jandrol.106.000968.
50. Li J, Qin Z, Liang Z. 2009. The prosurvival role of autophagy in resveratrol-induced cytotoxicity in human U251 glioma cells. BMC Cancer 9:215-224. http://dx.doi.org/10.1186/1471-2407-9-215.
51. Thompson SN. 1991. Applications of nuclear magnetic resonance in parasitology. J. Parasitol. 77:1-20. http://dx.doi.org/10.2307/3282548.
52. Adosraku RK, Anderson MM, Anderson GJ, Choi G, Croft SL, Yardley V, Phillipson JD, Gibbons WA. 1993. Proton NMR lipid profile of Leishmania donovani promastigotes. Mol. Biochem. Parasitol. 62:251-262. http://dx.doi.org/10.1016/0166-6851(93)90114-D.
53. O'Sullivan WJ, Edwards MR, Norton RS. 1989. The application of nuclear magnetic resonance spectroscopy to parasite metabolism. Parasitol. Today 5:79-82. http://dx.doi.org/10.1016/0169-4758(89)90007-0.
54. Van Assche T, Deschacht M, da Luz RA, Maes L, Cos P. 2011. Leishmania-macrophage interactions: insights into the redox biology. Free Radic. Biol. Med. 51:337-351. http://dx.doi.org/10.1016/j.freeradbiomed .2011.05.011.
55. Chung EY, Kim BH, Hong JT, Lee CK, Ahn B, Nam SY, Han SB, Kim Y. 2010. Resveratrol down-regulates interferon-γ-inducible inflammatory genes in macrophages: molecular mechanism via decreased STAT-1 activation. J. Nutr. Biochem. 22:902-909. http://dx.doi.org/10.1016/j.jnutbio.2010.07.012.
56. Hao E, Lang F, Chen Y, Zhang H, Cong X, Shen X, Su G. 2013. Resveratrol alleviates endotoxin-induced myocardial toxicity via the Nrf2 transcription factor. PLoS One 8:e69452. http://dx.doi.org/10.1371/journal.pone.0069452.
57. He X, Wang L, Szklarz G, Bi Y, Ma Q. 2012. Resveratrol inhibits paraquat-induced oxidative stress and fibrogenic response by activating the nuclear factor erythroid 2-related factor 2 pathway. J. Pharmacol. Exp.Ther. 342:81-90. http://dx.doi.org/10.1124/jpet.112.194142.
58. Paiva CN, Feijó DF, Dutra FF, Carneiro VC, Freitas GB, Alves LS, Mesquita J, Fortes GB, Figueiredo RT, Souza HS, Fantappié MR, Lannes-Vieira J, Bozza MT. 2012. Oxidative stress fuels Trypanosoma cruzi infection in mice. J. Clin. Invest. 122:2531-2542. http://dx.doi.org/10.1172/JCI58525.
59. Reguera RM, Balaña-Fouce R, Showalter M, Hickerson S, Beverley SM. 2009. Leishmania major lacking arginase are auxotrophic for polyamines but retain infectivity to susceptible BALB/c mice. Mol. Biochem. Parasitol. 165:48-56. http://dx.doi.org/10.1016/j.molbiopara.2009.01.001.
60. Kropf P, Fuentes JM, Fähnrich E, Arpa L, Herath S, Weber V, Soler G, Celada A, Modolell M, Müller I. 2005. Arginase and polyamine synthesis are key factors in the regulation of experimental leishmaniasis in vivo. FASEB J. 19:1000-1002. http://dx.doi.org/10.1096/fj.04-3416fje.
61. Suenaga F, Hatsushika K, Takano S, Ando T, Ohnuma Y, Ogawa H, Nakao A. 2008. A possible link between resveratrol and TGF-beta: resveratrol induction of TGF-beta expression and signaling. FEES Lett. 582: 586-590. http://dx.doi.org/10.1016/j.febslet.2008.01.024.
62. Cunningham M, Gilkeson G. 2011. Estrogen receptors in immunity and autoimmunity. Clin. Rev. Allergy Immunol. 40:66-73. http://dx.doi.org/10.1007/sI2016-010-8203-5.